Key result
Improved OSA severity after revascularization is linked to ~75% lower MACCE risk versus persistent OSA.
Why the study?
Recent randomized controlled trials failed to show cardiovascular benefits of treating OSA in intention-to-treat analyses, prompting investigation into whether untreated OSA persists after revascularization in CAD patients and how trajectory relates to MACCEs.
Does natural improvement in untreated obstructive sleep apnea reduce major cardiovascular and cerebrovascular events in adults with coronary artery disease following revascularization?
Cohort (n=204)
Does natural improvement in untreated obstructive sleep apnea reduce major cardiovascular and cerebrovascular events in adults with coronary artery disease following revascularization?
Effect estimate: HR 0.25 (95% CI 0.08-0.76)
p-value: p=0.015
In adults with coronary artery disease and untreated obstructive sleep apnea, natural improvement in OSA severity one year after revascularization is associated with a significantly lower risk of major cardiovascular and cerebrovascular events.
Post-revascularization OSA trajectory may inform risk stratification; hypothesis-generating for RCTs targeting persistent untreated OSA.
Rationale Recent randomized controlled trials failed to show cardiovascular benefits of treating obstructive sleep apnea (OSA) in intention-to-treat analyses which has been a matter of debate since publication of the results. Objectives To address whether untreated OSA persists after one year in adults with coronary artery disease (CAD) following revascularization and to explore whether major cardiovascular and cerebrovascular events (MACCEs) differ between the patients who persist vs improve in OSA severity. Measurements The study population included 119 CAD patients with moderate to severe OSA from the RICCADSA trial. All participants had an apnea-hypopnea index (AHI) ≥ 15/h and were randomized to no continuous positive airway pressure (CPAP) therapy (n = 81) or were not using the device (n = 38). Patients without OSA (AHI < 5/h) at baseline (n = 85) were included as a control group. Home sleep apnea tests were performed at baseline and after one year. Main Results The median AHI decreased from 24.5 (19.4-36.0/h) to 15.1 (8.2-27.3/h) and Oxygen Desaturation Index (4%) decreased from 14.8 (7.3-22.9/h) to 6.6/h (2.7-14.4/h) after one year (P < .001 for both). In all, 73 (61.3%) improved in OSA severity (59 had AHI 5-14.9/h and 14 had AHI < 5/h) whereas 46 (38.7%) had persistent OSA. The control group had a median AHI 4.4 (2.9-7.9/h) after one year. N-Terminal Pro-B-Type Natriuretic Peptide values decreased significantly in the overall cohort, with similar directional trends across OSA trajectory groups. The patients with improvement in OSA had significantly lower risk for MACCEs (Hazard Ratio 0.25, %95 CI 0.08-0.76; P = .015) compared to the patients with persistent OSA. Conclusions Most of the CAD patients with moderate to severe OSA improve in OSA severity one year after revascularization, probably due to the improved cardiac function, and have a decreased risk for MACCEs compared to individuals with persistent OSA. Identifying patients with persistent OSA after revascularization may help target those most likely to benefit from focused intervention, particularly in settings where CPAP therapy is not initiated or is poorly tolerated.
No takes yet. Share an insight, caveat, or question.
Peker et al. (2026) conducted a cohort in Coronary Artery Disease and Obstructive Sleep Apnea (n=204). Improvement in OSA severity vs. Persistent OSA was evaluated on Major cardiovascular and cerebrovascular events (MACCEs) (HR 0.25, 95% CI 0.08-0.76, p=0.015). Improvement in OSA severity one year after revascularization in CAD patients was associated with a significantly lower risk for MACCEs compared to persistent OSA (HR 0.25; 95% CI 0.08-0.76; P=0.015).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: